A carregar...
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial
IMPORTANCE: The PCSK9 inhibitor evolocumab reduced major vascular events in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial, yet the types and sizes of myocardial outcomes in FOURIER have not been previously explored. OBJECTIVE: To as...
Na minha lista:
| Publicado no: | JAMA Cardiol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7191470/ https://ncbi.nlm.nih.gov/pubmed/32347885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.0764 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|